Home » News » View News
World

AstraZeneca rejects sweetened Pfizer takeover bid

Font size

Posted: May 2, 2014 4:02 AM

Updated: May 2, 2014 4:03 AM

LONDON (AP) The board of pharmaceutical company AstraZeneca has rejected drug maker Pfizer's sweetened takeover offer.

The board says in a statement Friday that the terms are inadequate and substantially undervalue AstraZeneca. It says the board did not hesitate in rejecting the proposal.

THIS IS A BREAKING NEWS UPDATE. Check back soon for further information. AP's earlier story is below.

___

Drug maker Pfizer sweetened its takeover offer for U.K.-based AstraZeneca on Friday and outlined measures it hopes will ease British government concerns over the deal.

The Viagra maker said it is offering 50 pounds ($84) a share in cash and stock, a 7.3 increase on the previous bid. The offer values AstraZeneca at $106 billion.

"There is a highly compelling strategic, business and financial rationale for combining our businesses, with significant benefits for shareholders and stakeholders of both companies," Pfizer CEO Ian Read said in a statement announcing the offer.

AstraZeneca, which had shot down earlier takeover attempts, replied in a statement that its board would meet to discuss the latest offer.

Pfizer also sent a letter to Prime Minister David Cameron, promising to keep the country's corporate and tax residence in England and saying the "golden triangle of Oxford, Cambridge and London would represent a vital component" of the deal.

Critics fear the takeover could mean big job losses, and the potential loss of stature in the science sector in Britain has become a political issue.

"This does look a little bit like a transaction which has tax planning as a rationale," the opposition Labour Party's shadow business secretary, Chuka Umunna, told the BBC.

Pfizer Inc. is the world's second-biggest drugmaker by revenue while AstraZeneca PLC ranks eighth. AstraZeneca was created in 1999 through the merger of Sweden's Astra and Britain's Zeneca.

Topics: EU-Britain-Pfizer-AstraZeneca

KRGV is Social